Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

45 trials with published results (22%)

Research Maturity

145 completed trials (70% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.8%

14 terminated out of 207 trials

Success Rate

91.2%

+4.7% vs benchmark

Late-Stage Pipeline

30%

62 trials in Phase 3/4

Results Transparency

31%

45 of 145 completed with results

Key Signals

45 with results91% success14 terminated

Data Visualizations

Phase Distribution

194Total
Not Applicable (63)
Early P 1 (2)
P 1 (27)
P 2 (40)
P 3 (33)
P 4 (29)

Trial Status

Completed145
Unknown16
Recruiting14
Terminated14
Active Not Recruiting8
Withdrawn5

Trial Success Rate

91.2%

Benchmark: 86.5%

Based on 145 completed trials

Clinical Trials (207)

Showing 20 of 20 trials
NCT06451770Phase 1Recruiting

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT05355402Phase 2CompletedPrimary

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

NCT07406191Not ApplicableRecruiting

WB-EMS Effects on Cardiometabolic Risk Factors

NCT07004777Not ApplicableRecruitingPrimary

Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition

NCT06822790Phase 3RecruitingPrimary

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT07508930RecruitingPrimary

Russian Extreme Hypertriglyceridemia Registry

NCT07491172Phase 1Recruiting

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT06783881Phase 1Active Not RecruitingPrimary

Single-ascending Dose Study of Kylo-12 in Healthy Subjects

NCT07050134Not ApplicableEnrolling By InvitationPrimary

A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic Plaque

NCT05610280Phase 3CompletedPrimary

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

NCT07349615Phase 3Not Yet RecruitingPrimary

A Study of SHR-1918 In Participants With Hypertriglyceridemia

NCT05464784Phase 2Active Not Recruiting

MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

NCT05743868Not ApplicableRecruiting

Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different Insulin Resistance Phenotypes

NCT07028749Phase 2Active Not RecruitingPrimary

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

NCT07140809Phase 1RecruitingPrimary

a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia

NCT06471543Phase 1Active Not RecruitingPrimary

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

NCT03747224Phase 1Completed

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

NCT03783377Phase 1CompletedPrimary

Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

NCT03527069Phase 3CompletedPrimary

Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment

NCT05896254Phase 1CompletedPrimary

Study of MAR001 in Adults With Metabolic Dysfunction

Scroll to load more

Research Network

Activity Timeline